Enanta制药公司将在法院宣布与Pfizer's Pathlovid有关的专利无效后提出上诉。 Enanta Pharmaceuticals will appeal after a court invalidated its patent related to Pfizer's Paxlovid.

Enanta制药公司计划对马萨诸塞州法院的一项裁决提出上诉,这项裁决与辉瑞公司站在一起,宣布Enanta公司与COVID-19抗病毒药物和平社有关的专利无效。 Enanta Pharmaceuticals plans to appeal a Massachusetts court ruling that sided with Pfizer, invalidating Enanta's patent related to the COVID-19 antiviral drug Paxlovid. Enanta的诉讼声称专利受到侵犯,但法院驳回了他们的主张。 Enanta's lawsuit claimed patent infringement, but the court dismissed their claims. 尽管受到挫折,Enanta的首席执行官Jay Luly表示,该公司将继续在联邦巡回上诉法院为其专利进行辩护。 Despite the setback, Enanta's CEO, Jay Luly, stated the company will continue to defend its patents in the Court of Appeals for the Federal Circuit.